Overview

A Study Assessing the Efficacy and Safety of CBP-201

Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Suzhou Connect Biopharmaceuticals, Ltd.